Reported 2 days ago
Eli Lilly has taken a significant step to enhance its position in the competitive weight-loss medication market by partnering with Camurus to utilize its FluidCrystal technology for long-acting drug delivery. This innovation could potentially eliminate the need for weekly injections of its GLP-1 medicines, further appealing to patients and driving sales. Coupled with promising pipeline projects and strong revenue growth, Eli Lilly looks like a compelling investment opportunity despite concerns about market competition and tariffs.
Source: YAHOO